Cycle Launches Sajazir as Treatment Option for Acute HAE Attacks
by Mary Chapman | September 30, 2021
Share article via email
Cycle Pharmaceuticals has launched Sajazir, an injectable form of icatibant, as a new treatment option for acute attacks of hereditary angioedema (HAE) in adults.
Patients who use Sajazir can take advantage of Cycle Vita, the company's recently created rare disease product support hub.
Icatibant, also sold as Firazyr, by Takeda Pharmaceuticals, is approved by the U.S. Food and Drug Administration (FDA) for treating HAE, which is estimated to affect more than 7,000 people in the United States.
The new treatment, which comes in the form of a pre-filled 30 mg/3 ml syringe, treats swelling from HAE that can occur in the abdomen, extremities, genitals, face, or throat. It is designed to be self-administered under the skin, or subcutaneously, in the abdominal area.
"The launch of Sajazir gives the HAE community an exciting new treatment option," Zac Bohlen, Cycle's vice president of U.S. sales, said in a press release. "Cycle understands the importance of providing product support to complement the impact of therapeutic products."
May 27, 2021 News by Marisa Wexler MS
Glenmark Offering New Firazyr Generic in US
Cycle is encouraging HAE patients using Sajazir to check out its new platform. Cycle Vita offers an array of product information and support to individuals in the U.S. who have been prescribed a Cycle medication, as well as to healthcare providers who may not be up to speed on some of the disorders or on how they are treated.
Offering personalized, round-the-clock assistance, Cycle Vita helps patients navigate treatment insurance and payment processes, according to the company. Patients also may receive emotional support from the platform's team of registered nurses or other healthcare professionals, as well as guidance and training in self-administering Sajazir.
"Cycle Vita is an essential part of our core mission to better support patients with HAE and their families," said John Reid, director of patient hub services. "We will appropriately guide patients through every stage of their journey by streamlining the enrollment and finance process and providing ongoing treatment support in addition to the expertise of the patient's healthcare team."
Icatibant, the active ingredient of both Sajazir and Firazyr, prevents the signaling molecule bradykinin — which causes blood vessels to widen and become more permeable, and is found in excessive levels in HAE patients — from interacting with its receptor. By doing so, icatibant effectively interrupts the signaling cascade that otherwise would lead to swelling.
Found to have a good safety profile in multiple Phase 3 trials, icatibant has been shown to be effective in treating HAE swelling attacks.
The FDA last year approved Cipla's generic version of Firazyr — which was first approved in 2011 for treating acute HAE attacks in patients ages 18 and older. The original therapy was developed by Shire, now part of Takeda.
Takeda's patent for Firazyr expired in July 2019, making generic options of icatibant now available.
Mary Chapman Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d'Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled "Belle of the Concours."
Cycle Pharmaceuticals, Cycle Vita, Firazyr, HAE attacks, icatibant, injectable treatments, Sajazir
US Patients Underreport Burden of HAE to Their Doctors, Study Says
Takeda Canada Seeks AI, Digital Solutions With Innovation Challenge
New Gene Mutation Linked to HAE Type 1 Identified in Spanish Family
HAE Patients Have High Rate of Cancer, Canadian Study Suggests
Certain Conditions Found to Increase Risk of Angioedema in Older Adults
Pharming, Sanofi Extend Partnership to Manufacture Ruconest
Upper Airway Attacks Mostly Occur in Patients Ages 20-30, Smokers
Prepare to Light Up Buildings for Rare Disease Day 2022
Trial of HAE Gene-editing Therapy NTLA-2002 Doses Its First Patient
2 Family Members Make Swift Switch to Oral Orladeyo Successfully
January 13, 2022 News by Mary Chapman
January 10, 2022 News by Patricia Inacio PhD
January 6, 2022 News by Marisa Wexler MS
We use cookies to enhance your experience on our website. Privacy Policy Accept